{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T06:30:38Z","timestamp":1771655438426,"version":"3.50.1"},"reference-count":61,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,3,16]],"date-time":"2020-03-16T00:00:00Z","timestamp":1584316800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.gastrohep.2020.01.005","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T17:27:31Z","timestamp":1585762051000},"page":"273-283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Recomendaciones del Grupo Espa\u00f1ol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el tratamiento de pacientes con enfermedad inflamatoria intestinal asociada a espondiloartritis"],"prefix":"10.1016","volume":"43","author":[{"given":"Yago","family":"Gonz\u00e1lez-Lama","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jes\u00fas","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guillermo","family":"Bastida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roc\u00edo","family":"Ferreiro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Joven","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Juanola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatriz","family":"Sicilia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ra\u00fal","family":"Veroz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javier","family":"P Gisbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Chaparro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugeni","family":"Dom\u00e8nech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda","family":"Esteve","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Gomoll\u00f3n","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastrohep.2020.01.005_bib0310","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/gut.42.3.387","article-title":"Peripheral arthropathies in inflammatory bowel disease: Their articular distribution and natural history","volume":"42","author":"Orchard","year":"1998","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0315","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/ecco-jcc\/jjy191","article-title":"The pathogenesis of extraintestinal manifestations: Implications for IBD Research, Diagnosis, and Therapy","volume":"13","author":"Hedin","year":"2019","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0320","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.gastrohep.2017.03.012","article-title":"Screening of inflammatory bowel disease and spondyloarthritis for referring patients between Rheumatology and Gastroenterology","volume":"41","author":"Sanz Sanz","year":"2018","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0325","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00296-010-1635-7","article-title":"Relationship between diagnosis delay and disease features in Moroccan patients with ankylosing spondylitis","volume":"32","author":"Ibn Yacoub","year":"2012","journal-title":"Rheumatol Int"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0330","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/ibd.21506","article-title":"Development of the Crohn's disease digestive damage score, the Lemann score","volume":"17","author":"Pariente","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0335","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.autrev.2014.04.003","article-title":"Italian Expert Panel on the management of patients with coexisting spondyloarthritis and inflammatory bowel disease","volume":"13","author":"Olivieri","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0340","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.3748\/wjg.15.2449","article-title":"Clinical features and epidemiology of spondyloarthritides associated with inflammatory bowel disease","volume":"15","author":"Salvarani","year":"2009","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0345","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1177\/2040622314563929","article-title":"Management of arthropathy in inflammatory bowel diseases","volume":"6","author":"Peluso","year":"2015","journal-title":"Ther Adv Chronic Dis"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0350","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.reuma.2010.12.002","article-title":"[Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in spondyloarthritis except for psoriatic arthritis]","volume":"7","author":"Juanola Roura","year":"2011","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0355","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/ard.2010.133645","article-title":"The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general","volume":"70","author":"Rudwaleit","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0360","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1136\/ard.2009.108233","article-title":"The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part ii): Validation and final selection","volume":"68","author":"Rudwaleit","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0365","doi-asserted-by":"crossref","first-page":"2598","DOI":"10.1097\/MIB.0000000000000548","article-title":"Inflammatory articular disease in patients with inflammatory bowel disease: Result of the Swiss IBD Cohort Study","volume":"21","author":"Ditisheim","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0370","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1080\/003655201317097173","article-title":"Musculoskeletal manifestations in a population-based cohort of inflammatory bowel disease patients","volume":"36","author":"Salvarani","year":"2001","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0375","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1136\/annrheumdis-2014-205253","article-title":"The epidemiology of extra-articular manifestations in ankylosing spondylitis: A population-based matched cohort study","volume":"74","author":"Stolwijk","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0380","first-page":"511","article-title":"Prevalence of ankylosing spondylitis and other spondyloarthropathies among patients with inflammatory bowel disease: a population study (the IBSEN study)","volume":"29","author":"Palm","year":"2002","journal-title":"J Rheumatol"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0385","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1093\/ecco-jcc\/jjv213","article-title":"The first european evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease","volume":"10","author":"Harbord","year":"2016","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0390","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/apt.15294","article-title":"Three-year effectiveness and safety of vedolizumab therapy for inflammatory bowel disease: A prospective multi-centre cohort study","volume":"50","author":"Amiot","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0395","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.cgh.2018.09.035","article-title":"Retrospective analysis of safety of vedolizumab in patients with inflammatory bowel diseases","volume":"17","author":"Meserve","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0400","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1136\/annrheumdis-2016-210233","article-title":"An induction or flare of arthritis and\/or sacroilitis by vedolizumab in inflammatory bowel disease: a case series","volume":"76","author":"Varkas","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0405","first-page":"1483","volume":"74","author":"Poddubnyy","year":"2015","journal-title":"Development of an ASAS-endorsed recommendation for the early referral of patients with a suspicion of axial spondyloarthritis."},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0410","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1002\/art.21619","article-title":"Inflammatory back pain in ankylosing spondylitis: A reassessment of the clinical history for application as classification and diagnostic criteria","volume":"54","author":"Rudwaleit","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0415","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1136\/ard.2008.101501","article-title":"New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS)","volume":"68","author":"Sieper","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0420","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1136\/ard.2010.133488","article-title":"ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials\/epidemiological studies in axial spondyloarthritis","volume":"70","author":"Dougados","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0425","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1136\/ard.2011.151027","article-title":"2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis","volume":"70","author":"Braun","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0430","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1093\/rheumatology\/keu461","article-title":"Spanish Rheumatology Society and Hospital Pharmacy Society Consensus on recommendations for biologics optimization in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis","volume":"54","author":"Gonzalez-Alvaro","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0435","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/ecco-jcc\/jjw168","article-title":"3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management","volume":"11","author":"Gomollon","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0440","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1093\/ecco-jcc\/jjx009","article-title":"Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 2: Current Management","volume":"11","author":"Harbord","year":"2017","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0445","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.3899\/jrheum.140875","article-title":"Systematic review of treatments for psoriatic arthritis: 2014 update for the GRAPPA","volume":"41","author":"Coates","year":"2014","journal-title":"J Rheumatol"},{"issue":"Suppl 1","key":"10.1016\/j.gastrohep.2020.01.005_bib0450","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.reuma.2009.12.008","article-title":"[Management of spondyloarthritis (ESPOGUIA): Methodology and general data from the document]","volume":"6","author":"Carmona Ortells","year":"2010","journal-title":"Reumatol Clin"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0455","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.gastrohep.2013.11.014","article-title":"[Safe prescription recommendations for non steroidal anti-inflammatory drugs: Consensus document ellaborated by nominated experts of three scientific associations (SER-SEC-AEG)]","volume":"37","author":"Lanas","year":"2014","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0460","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(16)30002-2","article-title":"Effectiveness of non-steroidal anti-inflammatory drugs for the treatment of pain in knee and hip osteoarthritis: a network meta-analysis","author":"Da Costa","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0465","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/MCG.0000000000000421","article-title":"Role of nonsteroidal anti-inflammatory drugs in exacerbations of inflammatory bowel disease","volume":"50","author":"Long","year":"2016","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0470","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1097\/MIB.0000000000000165","article-title":"Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: Pathophysiology and clinical associations","volume":"20","author":"Habib","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0475","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.medcli.2015.09.022","article-title":"[Appropriate prescription, adherence and safety of non-steroidal anti-inflammatory drugs]","volume":"146","author":"Sostres","year":"2016","journal-title":"Med Clin (Barc)"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0480","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1007\/s00228-009-0719-3","article-title":"Exacerbation of inflammatory bowel diseases associated with the use of nonsteroidal anti-inflammatory drugs: Myth or reality?","volume":"65","author":"Kefalakes","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0485","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3390\/ph8030512","article-title":"Use of cyclo-oxygenase inhibitors is not associated with clinical relapse in inflammatory bowel disease: A case-control study","volume":"8","author":"Hensley","year":"2015","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0490","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.cgh.2005.12.002","article-title":"Safety of celecoxib in patients with ulcerative colitis in remission: A randomized, placebo-controlled, pilot study","volume":"4","author":"Sandborn","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0495","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1111\/j.1572-0241.2006.00384.x","article-title":"The gastrointestinal safety and effect on disease activity of etoricoxib, a selective cox-2 inhibitor in inflammatory bowel diseases","volume":"101","author":"El Miedany","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0500","doi-asserted-by":"crossref","first-page":"599","DOI":"10.36076\/ppj.2015\/18\/599","article-title":"Coxib's safety in patients with inflammatory bowel diseases: A meta-analysis","volume":"18","author":"Ribaldone","year":"2015","journal-title":"Pain Physician"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0505","first-page":"Cd007744","article-title":"Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease","author":"Miao","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0510","first-page":"2860","article-title":"Spondyloarthropathy is underestimated in inflammatory bowel disease: Prevalence and HLA association","volume":"27","author":"De Vlam","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0515","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s10067-015-3074-z","article-title":"Occult spondyloarthritis in inflammatory bowel disease","volume":"35","author":"Bandinelli","year":"2016","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0520","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1053\/gast.2001.28674","article-title":"Etanercept for active Crohn's disease: A randomized, double-blind, placebo-controlled trial","volume":"121","author":"Sandborn","year":"2001","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0525","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jbspin.2011.10.001","article-title":"Development of inflammatory bowel disease during anti-TNF-alpha therapy for inflammatory rheumatic disease: A nationwide series","volume":"79","author":"Toussirot","year":"2012","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0530","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/art.22669","article-title":"Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents","volume":"57","author":"Braun","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0535","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/apt.15397","article-title":"Systematic review with meta-analysis: Risk of new onset IBD with the use of anti-interleukin-17 agents","volume":"50","author":"Yamada","year":"2019","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0540","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1136\/gutjnl-2011-301668","article-title":"Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: Unexpected results of a randomised, double-blind placebo-controlled trial","volume":"61","author":"Hueber","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0545","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.gastrohep.2014.12.003","article-title":"[Vedolizumab in the treatment of Crohn's disease]","volume":"38","author":"Gisbert","year":"2015","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0550","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2019.01.008","article-title":"Vedolizumab has no efficacy on articular manifestations in patients with spondyloarthritis associated with inflammatory bowel disease","author":"Paccou","year":"2019","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0555","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/annrheumdis-2013-204248","article-title":"Ustekinumab for the treatment of patients with active ankylosing spondylitis: Results of a 28-week, prospective, open-label, proof-of-concept study (TOPAS)","volume":"73","author":"Poddubnyy","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0560","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1002\/art.40728","article-title":"Three multicenter, randomized, double-blind, placebo-controlled studies evaluating the efficacy and safety of ustekinumab in axial spondyloarthritis","volume":"71","author":"Deodhar","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0565","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.gastrohep.2013.01.002","volume":"36","author":"Cabriada","year":"2013","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0570","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.gastrohep.2014.10.002","volume":"38","author":"Gomollon","year":"2015","journal-title":"Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0575","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/ecco-jcc\/jjy125","article-title":"Incidence of arthritis\/arthralgia in inflammatory bowel disease with long-term vedolizumab treatment: Post hoc analyses of the GEMINI Trials","volume":"13","author":"Feagan","year":"2019","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0580","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/apt.14419","article-title":"Impact of vedolizumab therapy on extra-intestinal manifestations in patients with inflammatory bowel disease: A multicentre cohort study nested in the OBSERV-IBD cohort","volume":"47","author":"Tadbiri","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0585","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1093\/ecco-jcc\/jjv027","article-title":"Optimal doses of methotrexate combined with anti-TNF therapy to maintain clinical remission in inflammatory bowel disease","volume":"9","author":"Colman","year":"2015","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0590","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/gutjnl-2013-304984","article-title":"Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial","volume":"63","author":"Peyrin-Biroulet","year":"2014","journal-title":"Gut"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0595","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1155\/2014\/737349","article-title":"Physician global assessments or blood tests do not predict mucosal healing in ulcerative colitis","volume":"28","author":"Brahmania","year":"2014","journal-title":"Can J Gastroenterol Hepatol"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0600","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/ecco-jcc\/jjy113","article-title":"ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 1: Initial diagnosis, monitoring of known IBD, detection of complications","volume":"13","author":"Maaser","year":"2019","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0605","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/ecco-jcc\/jjy114","article-title":"ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspects","volume":"13","author":"Sturm","year":"2019","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.gastrohep.2020.01.005_bib0610","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/apt.14368","article-title":"Review article: Consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases","volume":"46","author":"Mitrev","year":"2017","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Gastroenterolog\u00eda y Hepatolog\u00eda"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570520300728?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0210570520300728?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T12:43:23Z","timestamp":1759322603000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0210570520300728"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":61,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0210570520300728"],"URL":"https:\/\/doi.org\/10.1016\/j.gastrohep.2020.01.005","relation":{},"ISSN":["0210-5705"],"issn-type":[{"value":"0210-5705","type":"print"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recomendaciones del Grupo Espa\u00f1ol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre el tratamiento de pacientes con enfermedad inflamatoria intestinal asociada a espondiloartritis","name":"articletitle","label":"Article Title"},{"value":"Gastroenterolog\u00eda y Hepatolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastrohep.2020.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Espa\u00f1a, S.L.U.","name":"copyright","label":"Copyright"}]}}